Currently, a phase 1 / 2 trial using CLDN6-targeting CAR-NK cells is recruiting patients suffering from advanced ovarian, endometrial cancer, or GCT (NCT05410717), while other phase 1 / 2 trials using CLDN6 CAR-T cells (BNT211; NCT04503278) or mRNA encoded bispecific T cell engaging antibody targeting CD3 and CLDN6 (BNT142; NCT05262530) are also currently recruiting for the treatment of solid tumors. The gene discussed is CLDN6; the disease is granular cell tumor.